Last week, the political landscape shifted for one of the nation’s most powerful regulatory bodies. President Trump officially nominated Dr. Heidi Overton, a seasoned White House domestic policy aide, to serve as the Commissioner of the Food and Drug Administration (FDA). If confirmed by the Senate, Dr. Overton will inherit an agency standing at a critical juncture, tasked with navigating the complex, high-stakes, and often contentious regulatory environment of the Center for Tobacco Products (CTP).
The nomination comes at a time when the CTP is facing intense scrutiny. Over the past two decades, the agency’s policy decisions have drawn criticism for creating unintended consequences that have inadvertently hindered harm-reduction efforts. By restricting access to alternative tobacco products (ATPs)—which research suggests are significantly less harmful than traditional combustible cigarettes—the FDA has arguably pushed consumers toward a thriving, unregulated, and dangerous illicit market.
The Chronology of a Regulatory Bottleneck
The history of the CTP’s regulatory approach is marked by a transition from broad oversight to a rigid, bureaucratic framework that has struggled to keep pace with industry innovation.
- The Early Years (2009–2016): Following the Family Smoking Prevention and Tobacco Control Act of 2009, the FDA gained authority over tobacco products. However, the initial focus remained largely on traditional cigarettes, leaving the burgeoning market for e-cigarettes and vapor products in a regulatory gray area for several years.
- The PMTA Mandate (2016–2020): The FDA issued the "Deeming Rule," extending its authority to include e-cigarettes, cigars, and other novel products. This mandated that all manufacturers submit Premarket Tobacco Product Applications (PMTAs) to prove their products were "appropriate for the protection of public health."
- The Backlog Crisis (2021–2024): As the deadline for applications passed, the CTP was inundated with millions of submissions. The agency’s inability to process these applications in a timely manner led to widespread industry confusion, litigation, and the effective banning of countless products without a formal review process.
- The Pivot (2025–Present): Facing immense pressure from courts and industry advocates, the CTP managed a significant turnaround in 2025, reducing the PMTA backlog by approximately 70 percent. This year, the agency has begun to show further flexibility, allowing for some leniency for products currently under review, signaling a potential thaw in its previously adversarial posture.
The Economics of Regulation: Why the Current Process Fails
At the heart of the debate is the PMTA process itself. To legally sell a nicotine product in the United States, a company must secure a Marketing Granted Order (MGO). This process is not only scientifically rigorous but also financially prohibitive.
Each individual product or "SKU" requires a separate, exhaustive application. While the FDA initially estimated the cost of a single PMTA at approximately $333,000, industry reports suggest that the reality is closer to several million dollars per SKU. For a company with a diverse product line, compliance costs can easily exceed $100 million.
The economic implications of these barriers are profound. By making the cost of entry so high, the FDA has effectively fostered a climate of industry consolidation. Smaller, innovative firms are often squeezed out, leaving the market to a few deep-pocketed incumbents. More importantly, as the FDA itself admitted when the rules were first drafted, these burdens lead to "additional product exit" and a "reduction in variety." When consumers lose access to the legal alternatives they prefer, they do not necessarily quit nicotine; they migrate to the illicit market.
Supporting Data: The Case for Harm Reduction
The data supporting a move toward harm reduction is compelling. Smoking remains the leading cause of preventable death in the United States, responsible for approximately 450,000 deaths annually. Research consistently demonstrates that ATPs—such as e-cigarettes, heat-not-burn devices, and nicotine pouches—carry a significantly lower risk profile than combustible cigarettes.
However, the CTP’s restrictive approach has created a "vaping market disaster." To date, the FDA has authorized only a handful of e-cigarette brands. Consequently, nearly 70 percent of e-cigarette sales in the U.S. consist of unauthorized products, a figure that jumps to 97.6 percent for disposable systems.
The trend in youth usage also provides a strong argument for regulatory recalibration. The FDA’s own 2025 National Youth Tobacco Survey (NYTS) reported that only 5.2 percent of middle and high school students currently use vapor products, down from 5.9 percent in 2024 and nearly half of the 9.4 percent reported in 2022. By contrast, 8.7 percent of adolescents report using marijuana—a substance that does not face the same regulatory scrutiny as tobacco alternatives. As youth interest in vaping continues to wane, the justification for blanket bans on flavored, lower-harm products becomes increasingly difficult to sustain.
Official Responses and Judicial Pressure
The FDA’s regulatory philosophy has not gone unchallenged. The Supreme Court recently clarified that while the FDA can change its requirements for applications after the fact, it does not necessarily have to exercise that power to engage in blanket denials.
Furthermore, the Fifth Circuit Court of Appeals recently issued a ruling that signaled growing judicial impatience with the FDA’s opaque review process. The court’s decision suggests that the agency may be failing to properly assess the economic impact of its rules, particularly on small manufacturers. These legal developments provide a roadmap for Dr. Overton: the CTP does not need to wait for a court order to implement common-sense reforms. Increased transparency, clear criteria for approval, and a standardized, predictable timeline for reviews are well within the agency’s existing mandate.
Implications for Dr. Overton’s Tenure
If Dr. Overton is confirmed, her tenure will likely be defined by whether she chooses to institutionalize the progress made in 2025 or retreat to the restrictive policies of the past. To truly reform the CTP, she should consider the following strategic pillars:
1. The 180-Day "Shot Clock"
The CTP is legally expected to make decisions on PMTAs within 180 days, yet it faces no consequences for missing these deadlines. Implementing a policy where any application that exceeds the 180-day window is granted conditional approval would create a powerful incentive for the agency to act with efficiency and diligence.
2. Transparent Standards
The term "appropriate for the protection of public health" is currently interpreted with frustrating subjectivity. The CTP should publish specific, evidence-based guidance outlining exactly what studies are required for approval. This would eliminate the "moving goalpost" phenomenon that has characterized the last decade of product submissions.
3. Targeting the Illicit Market Through Legal Competition
Enforcement actions, such as the record-breaking $86.5 million seizure of illegal e-cigarettes in September 2025, are necessary but insufficient. Smuggled products will continue to flood the market as long as the demand for legal, diverse, and high-quality alternatives remains unmet. By authorizing a wider range of products, the FDA can draw consumers back into a regulated, tax-compliant, and safer legal market, effectively starving the illicit trade of its customer base.
Conclusion: A Moral Imperative
The challenge facing Dr. Overton is not merely administrative; it is a matter of public health. For too long, the CTP has functioned as a gatekeeper that has kept life-saving alternatives from the very smokers they are meant to assist. The agency has made undeniable strides in clearing its backlog, but the structural flaws in its regulatory approach remain.
By embracing a policy of harm reduction, providing clarity to manufacturers, and replacing illicit market share with authorized, safer alternatives, the new leadership at the FDA has the potential to save hundreds of thousands of lives. Whether Dr. Overton can navigate the bureaucratic inertia and political pressures to achieve these goals will be one of the most closely watched aspects of the incoming administration’s health agenda. The path forward is clear: innovation and public health are not mutually exclusive, provided the regulator is willing to facilitate, rather than obstruct, the transition away from combustible tobacco.
